How to Choose a Hospital for — Targeted Therapy in India

Neither is automatically better. Government cancer institutes often have highly experienced specialists and lower costs — and are worth prioritising if PMJAY coverage applies to you. The disadvantage is usually waiting time: for a first appointment, for testing results, and for a treatment slot. Dedicated private cancer centres typically have shorter waits and more predictable scheduling, at higher out-of-pocket cost. The right choice depends on how urgently treatment needs to start, where you live, and what your coverage allows.

For most targeted therapies, no. Treatment is given as oral tablets or short infusions — often every week to every few weeks — meaning you will return regularly over many months. Travelling across the country for every visit is impractical and hard on someone who is already unwell. Travelling once for a second opinion, or to have biomarker testing reviewed by a specialist, is often worthwhile. After that, continuing at a reliable centre near home is usually the better choice for your quality of life.

Yes. Transferring is possible at most points in treatment. What you need is your complete medical record: pathology reports, biomarker test results, imaging, and a treatment summary from your current oncologist. Most centres will accept a transfer with these documents in hand. The main practical risk is a gap in treatment during the transition, which is worth discussing with both teams before you move. You are not obligated to stay with a centre that is not meeting your needs.

Ask directly: how many patients with this specific diagnosis do you see each month? You can also ask whether the oncologist participates in tumour board discussions for your cancer type, and whether they have treated patients with your specific mutation or biomarker before. This is a reasonable question, and a good oncologist will welcome it. If the answer is vague or the volume is low, that is information worth weighing when you make your decision.

Yes, in most cases — especially if comprehensive biomarker testing has not been done, if the recommended treatment is expensive or carries significant side effects, or if you are unsure whether the plan matches current guidelines from bodies like NCCN or ESMO. A second opinion does not mean you distrust your oncologist. It means you are making a significant decision and want confidence that it is the right one. Most oncologists support second opinions, and the records you need are yours to ask for.

Start by getting the full list of network hospitals from your insurer, then apply the same criteria to that list: is biomarker testing available here, is your drug administered at this centre, and does an oncologist with experience in your cancer type practise here? If none of the covered hospitals meet those criteria, ask your insurer about a referral exception. Some policies allow this when the specific treatment is not available within the network. Ask for any exception to be confirmed in writing before you begin treatment.